INVICTA DIAGNOSTIC LTD Fair Value
INVICTA · Healthcare · Current price ₹68.8
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹46 | 15% ROE fading to 12% over ~10 yrs, on ₹40 book |
| Relative P/E | ₹253 | EPS × 64.7 peer-median P/E |
| Graham floor | ₹59 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is INVICTA DIAGNOSTIC LTD undervalued?
DocStoX estimates the fair value of INVICTA DIAGNOSTIC LTD at ₹106 per share, versus the current market price of ₹69. That puts the stock about +54.4% below our fair-value estimate, which we read as "Strong Buy". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹46), Relative P/E (₹253), Graham floor (₹59). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹46 (bear) to ₹106 (base) to ₹253 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on INVICTA DIAGNOSTIC LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.